Author

Takahiro Morito

RIKEN Center for Brain ScienceORCID 0009-0002-8611-9151Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Neuroscience· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:mouse· 2

Frequent Co-Authors

Hiroki SasaguriiD· 2 shared Makoto HiguchiiD· 2 shared Naoko KamanoiD· 2 shared Naoto WatamuraiD· 2 shared Takaomi C. SaidoiD· 2 shared A. Miyawaki· 1 shared Andrew RobinsoniD· 1 shared David M. A. ManniD· 1 shared

Activity by Year

2024-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 39 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersNeuroscience

Hiroki SasaguriORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Single MAPT knock-in mouse models of frontotemporal dementia for sharing with the neurodegenerative research community

Takahiro Morito, Mohan Qi, Naoko Kamano, Hiroki Sasaguri, Sumi Bez, Martha S. Foiani, Karen Duff, Seico Benner, Toshihiro Endo, Hiroshi Hama, Hiroshi Kurokawa, A. Miyawaki, Hiroshi Mizuma, Naruhiko Sahara, Masafumi Shimojo, , Naoto Watamura

The paper describes the development of triple MAPT mutation knock-in mice that exhibit early tau pathology and behavioral abnormalities, useful for studying frontotemporal dementia and related tauopathies.

bioRxiv · Nov 15, 2024 · PreprintNeuroscience

Metabolic resistance of Abeta3pE-42, epitope of the anti-Alzheimer therapeutic antibody, donanemab.

Nobuhisa Iwata, Satoshi Tsubuki, Misaki Sekiguchi, Kaori Watanabe-Iwata, Yukio Matsuba, Naoko Kamano, Ryo Fujioka, Risa Takamura, Naoto Watamura, Naomasa Kakiya, Naomi Mihira, Takahiro Morito, Keiro Shirotani, David M. A. Mann, Andrew Robinson, , Takaomi C. Saido

This paper investigates the metabolic stability and deposition of A{beta}3pE-42, a target of the Alzheimer's antibody donanemab, showing it is more stable than other A{beta}X-42 species and accumulates with age.

Life Science Alliance · Sep 30, 2024Peer-reviewedNeuroscience